{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-025957","form_type":"8-K","ticker":"QTTB","cik":"0001661998","company_name":"Q32 Bio Inc.","filed_at":"2022-02-03T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.680255+00:00","generated_at":"2026-06-27T11:45:43.309078+00:00","sec_items":["1.01","5.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Homology forms AAV manufacturing JV with Oxford; receives $130M; owns 20% of Newco","bullets":["Homology receives $130M upfront from Oxford Biomedica; Oxford invests $50M additional into Newco.","Post-closing OXB owns 80% and Homology 20% of Oxford Biomedica Solutions LLC.","Tim Kelly, Homology's COO, becomes CEO and Chairman of Newco; Arthur Tzianabos on board.","Oxford Biomedica CEO John Dawson retires; Dr. Roch Doliveux named interim CEO.","Transaction expected to close Q1 2022, subject to HSR antitrust clearance."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-025957","json":"https://secwatch.observer/filing/0001193125-22-025957.json","markdown":"https://secwatch.observer/filing/0001193125-22-025957.md","text":"https://secwatch.observer/filing/0001193125-22-025957.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1661998/000119312522025957/0001193125-22-025957-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1661998/000119312522025957/d306124d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T11:45:43.309078+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ba3da5f18c","claim":"Tim Kelly departed as Chief Operating Officer at Q32 Bio Inc..","evidence_excerpt":"Effective as of the Closing, Tim Kelly will assume the role of Chief Executive Officer and Chairman of the Board of Newco and will no longer serve as the Chief Operating Officer of Homology.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1661998/000119312522025957/0001193125-22-025957-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"will no longer serve"},{"label":"Role","value":"Chief Operating Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}